New vitamin D analogs and changing therapeutic paradigms

Kidney International

Volumn 79, Issue 7, 2011, Pages 702-707

  Cunningham, John ^a   Zehnder, Daniel ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

activated vitamin D; cardiovascular disease; hyperparathyroidism; kidney disease

Indexed keywords

22 OXACALCITRIOL; CALCITRIOL; DOXERCALCIFEROL; PARICALCITOL; PLACEBO; VITAMIN D DERIVATIVE;

ARTICLE; BLOOD PRESSURE REGULATION; CALCIUM BLOOD LEVEL; CALCIUM HOMEOSTASIS; CHRONIC KIDNEY DISEASE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYDROXYLATION; HYPERPARATHYROIDISM; KIDNEY FUNCTION; MINERAL METABOLISM; NONHUMAN; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RENAL PROTECTION; SIDE EFFECT; VITAMIN D METABOLISM;

EID: 79952696881     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.387     Document Type: Article

References (31)

1. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-38. (Pubitemid 44967731)
2. Palmer SC, McGregor DO, Macaskill P et al. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 2007; 147: 840-853. (Pubitemid 351664426)
3. Palmer SC, McGregor DO, Craig JC et al. Vitamin D compounds for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009; CD008175: Issue 4.
4. Palmer SC, McGregor DO, Craig JC et al. Vitamin D compounds for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev 2009; CD005633: Issue 4.
5. Brickman AS, Coburn JW, Norman AW. Action of 1,25-dihydroxy- cholecalciferol, a potent, kidney-produced metabolite of vitamin D, in uremic man. N Engl J Med 1972; 287: 891-895.
6. Brown AJ, Ritter CR, Finch JL et al. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 1989; 84: 728-732. (Pubitemid 19228340)
7. 2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats. Am J Kidney Dis 1998; 32: S40-S47. (Pubitemid 28487834)
8. Tamura S, Ueki K, Mashimo K et al. Comparison of the efficacy of an oral calcitriol pulse or intravenous 22-oxacalcitriol therapies in chronic hemodialysis patients. Clin Exp Nephrol 2005; 9: 238-243. (Pubitemid 41414124)
9. Ogata H, Koiwa F, Shishido K et al. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism. Ther Apher Dial 2007; 11: 202-209. (Pubitemid 46716158)
10. Sprague SM, Llach F, Amdahl M et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63: 1483-1490. (Pubitemid 36350014)
11. Gallieni M, Kamimura S, Ahmed A et al. Kinetics of monocyte 1 alpha-hydroxylase in renal failure. Am J Physiol 1995; 268: F746-F753.
12. Marco MP, Craver L, Betriu A et al. Influence of vitamin D receptor gene polymorphisms on mortality risk in hemodialysis patients. Am J Kidney Dis 2001; 38: 965-974. (Pubitemid 33022173)
13. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456. (Pubitemid 36910023)
14. Teng M, Wolf M, Ofsthun MN et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125. (Pubitemid 41710323)
15. Tentori F, Hunt FC, Stidley CA et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70: 1858-1865. (Pubitemid 44684819)
16. Naves-Diaz M, Alvarez-Hernandez D, Passlick-Deetjen J et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 2008; 74: 1070-1078.
17. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780. (Pubitemid 44215354)
18. Shinaberger CS, Kopple JD, Kovesdy CP et al. Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1769-1776.
19. Xiang W, Kong J, Chen S et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005; 288: E125-E132. (Pubitemid 40023798)
20. Simpson RU, Hershey SH, Nibbelink KA. Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J Steroid Biochem Mol Biol 2007; 103: 521-524. (Pubitemid 46420533)
21. Zhou C, Lu F, Cao K et al. Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int 2008; 74: 170-179. (Pubitemid 351915078)
22. Bodyak N, Ayus JC, Achinger S et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci USA 2007; 104: 16810-16815. (Pubitemid 350210947)
23. Lopez I, Mendoza FJ, Aguilera-Tejero E et al. The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int 2008; 73: 300-307.
24. Lomashvili KA, Garg P, Narisawa S et al. Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcification. Kidney Int 2008; 73: 1024-1030. (Pubitemid 351543906)
25. Bouillon R, Verlinden L, Eelen G et al. Mechanisms for the selective action of Vitamin D analogs. J Steroid Biochem Mol Biol 2005; 97: 21-30. (Pubitemid 41546210)
26. Bouillon R, Carmeliet G, Verlinden L et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 2008; 29: 726-776.
27. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005; 289: F8-28.
28. Holick MF. Resurrection of vitamin D deficiency and rickets. J Clin Invest 2006; 116: 2062-2072. (Pubitemid 44162310)
29. Cunningham J. Transplantation: supplemental vitamin D: will do no harm and might do good. Nat Rev Nephrol 2009; 5: 614-615.
30. Liu PT, Stenger S, Li H et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006; 311: 1770-1773.
31. London GM, Guerin AP, Verbeke FH et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007; 18: 613-620. (Pubitemid 46193327)